UNKNOWN ELBOW
Report
- Report Number
- 0001825034-2014-08222
- Event Type
- Injury
- Date Received
- October 24, 2014
- Report Date
- September 26, 2014
- Manufacturer
- BIOMET ORTHOPEDICS
- Product Code
- JDC
- PMA / PMN Number
- PUNKNOWN
- Removal / Correction Number
- N/A
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- JA
- Reporter Occupation
- PHYSICIAN
Narratives
CURRENT INFORMATION IS INSUFFICIENT TO PERMIT CONCLUSIONS AS TO THE CAUSE OF THE EVENTS. EVENT DETAILS AND PRODUCT IDENTIFICATION WAS NOT PROVIDED FOR THE PATIENTS MENTIONED IN THE JOURNAL ARTICLE. THE FOLLOWING SECTIONS COULD NOT BE COMPLETED WITH THE LIMITED INFORMATION PROVIDED. DATE OF EVENT - UNKNOWN; BRAND NAME - UNKNOWN; CATALOG NUMBER, LOT NUMBER AND EXPIRATION DATE - UNKNOWN; DATE IMPLANTED - UNKNOWN; DATE EXPLANTED - UNKNOWN. (B)(6). THE 510K NUMBER - UNKNOWN; MANUFACTURE DATE ¿ UNKNOWN.
INFORMATION WAS RECEIVED BASED ON AN ARTICLE RECEIVED, "FLEXOR CARPI ULNARIS MUSCLE FLAP FOR SOFT TISSUE RECONSTRUCTION AFTER TOTAL ELBOW ARTHROPLASTY," WHICH REPORTS THE POSITIVE CLINICAL RESULTS THE AUTHORS EXPERIENCED BY USING A FLEXOR CARPI ULNARIS (FCU) MUSCLE FLAP FOR SOFT TISSUE RECONSTRUCTION. THE STUDY FOLLOWED TWO PATIENTS WHO UNDERWENT TOTAL ELBOW ARTHROPLASTY; ONLY ONE OF THE TWO PATIENTS RECEIVED A BIOMET ELBOW IMPLANT. THE JOURNAL ARTICLE REPORTS THAT IMMEDIATELY AFTER THE TOTAL ELBOW ARTHROPLASTY, BLISTERING OCCURRED ON THE TIP OF THE OLECRANON. AN AREA OF SKIN NECROSIS OCCURRED TWO WEEKS AFTER SURGERY. THE PATIENT UNDERWENT A RECONSTRUCTION USING THE FCU MUSCLE FLAP AND NO POSTOPERATIVE COMPLICATIONS WERE REPORTED. THE AUTHORS CONCLUDE THAT THE FCU MUSCLE FLAP IS THE LEAST INVASIVE TREATMENT AND SHOULD BE SELECTED FIRST (ABOVE OTHER MUSCLES) WHEN RECONSTRUCTING SOFT TISSUE.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 678834 | UNKNOWN ELBOW | PROSTHESIS, ELBOW | JDC | BIOMET ORTHOPEDICS | N/A | UNKNOWN |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 65 YR | Hospitalization| R |